Table 1.
Overall characteristics across included samples (k = 45)
| Sample Characteristics | Mean (SD) | K |
|---|---|---|
| Age | 38.0 (6.6) | 45 |
| Percent Female | 37.6 (9.7) | 45 |
| Percent Diagnosisa | 38 | |
| Schizophrenia | 83.8 (16.8) | – |
| Schizoaffective | 12.9 (13.9) | – |
| Other Psychosis | 3.1 (9.2) | – |
| Length of illness | 13.7 (7.0) | 21 |
| Chlorpromazine equivalent doses | 482.4 (212.2) | 21 |
|
| ||
| Study Characteristics | Mean (SD) | K |
|
| ||
| Data source (k, %) | 45 | |
| Published Articleb | 42 (93.3) | – |
| Conference Abstract | 3 (6.7) | – |
| Median Year (range) | 2015 (1998–2017) | 45 |
| Mean Sample size (range) | 61.8 (11–486) | 45 |
| Study Location (k, %) | 45 | |
| Asia | 10 (22.2) | – |
| Europe | 11 (24.4) | – |
| North America | 24 (53.3) | – |
a
All included samples had schizophrenia-spectrum disorder diagnoses.
b
Includes studies that were published as both a conference abstract and article.